Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Common Stock · CUSIP: 03753U106

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Wellington Management Group LLP

    Shares: 11,833,409.00 · Class: 9.5%

  • Wellington Group Holdings LLP

    Shares: 11,833,409.00 · Class: 9.5%

  • Wellington Investment Advisors Holdings LLP

    Shares: 11,833,409.00 · Class: 9.5%

  • Wellington Management Company LLP

    Shares: 11,833,409.00 · Class: 9.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902219-25-000121
Form type
SCHEDULE 13G/A
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Feb 10, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub